Divi's Laboratories Limited — Investor Meet, 29-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Divi's Labs reported Q4 FY26 consolidated income of ₹2,986 Cr & PAT of ₹751 Cr. Full-year income hit ₹11,067 Cr, with PAT at ₹2,568 Cr. Generic volumes stayed stable but pricing is competitive. Custom synthesis has strong customer engagement & active pipeline. Management noted Q4 supply chain disruptions due to geopolitical tensions & higher freight costs, expected to continue in Q1. Divi's aims for double-digit revenue growth with stable margins. ₹1,544 Cr capex capitalized, ₹2,113 Cr ongoing. Expanding peptides & contrast media; commercialization depends on customer approvals. Confident in execution despite external challenges.